开放期刊系统

生物制剂治疗过敏性支气管肺曲霉病的研究进展

王朵, 龚建化*

摘要

过敏性支气管肺曲霉病（Allergic bronchopulmonary aspergillosis,ABPA）是一种复杂肺部疾病，它们在慢性肺病患者的气道中定植。其常规治疗方法是使用皮质醇激素加抗真菌药，这种治疗虽旨在减缓疾病进展和控制炎症，但会使许多患者依赖激素并受其长期使用的不良影响，在过去的两年间，新型生物制剂，被医生超说明书运用，这主要是依据它们对于炎症细胞和介质的作用，而这些细胞和介质在和ABPA相关的免疫路径里有着关键作用。本研究致力于概述针对ABPA的新型生物制剂靶向疗法的最新研究动态。

关键词

过敏性支气管肺曲霉病；奥马珠单抗；度普利尤单抗；美泊利单抗；特泽鲁单抗

全文:

PDF

参考

[1]Patel A R, Patel A R, Singh S, et al. Diagnosing Allergic Bronchopulmonary Aspergillosis: A Review [J]. Cureus, 2019, 11(4).

[2]施静,刘先胜.变应性支气管肺曲霉病的诊治进展[J].临床内科杂志,2023,40(08):508-512.

[3]Elphick H E, Southern K W. Antifungal therapies for allergic bronchopulmonary aspergillosis in people with cystic fibrosis [J]. The Cochrane database of systematic reviews, 2014, (11): Cd002204.

[4]Moss R B. Severe Fungal Asthma: A Role for Biologics and Inhaled Antifungals [J]. Journal of fungi (Basel, Switzerland), 2023, 9(1).

[5]Jin M, Douglass J A, Elborn J S, et al. Omalizumab in Allergic Bronchopulmonary Aspergillosis: A Systematic Review and Meta-Analysis [J]. The journal of allergy and clinical immunology In practice, 2023, 11(3): 896-905.

[6] Tracy M C, Okorie C U A, Foley E A, et al. Allergic Bronchopulmonary Aspergillosis [J]. Journal of fungi (Basel, Switzerland), 2016, 2(2).

[7]Chaudhary N, Datta K, Askin F B, et al. Cystic fibrosis transmembrane conductance regulator regulates epithelial cell response to Aspergillus and resultant pulmonary inflammation [J]. American journal of respiratory and critical care medicine, 2012,185(3):301-310.

[8]Agarwal R, Sehgal I S, Dhooria S, et al. Allergic bronchopulmonary aspergillosis [J]. The Indian journal of medical research, 2020, 151(6): 529-549.

[9]Schuyler M. The Th1/Th2 Paradigm in Allergic Bronchopulmonary Aspergillosis [J]. Journal of Laboratory and Clinical Medicine, 1998, 131(3).

[10]Easthope S, Jarvis B. Omalizumab [J]. Drugs, 2001, 61(2): 253-260; discussion 261.

[11]Chen X, Zhi H, Wang X, et al. Efficacy of Biologics in Patients with Allergic Bronchopulmonary Aspergillosis: A Systematic Review and Meta-Analysis [J]. Lung,2024,202(4): 367-383.

[12]肖幸幸,韩国敬.奥马珠单抗治疗变应性支气管肺曲霉菌病的临床疗效分析[J].临床肺科杂志,2018,23(12):2219-2221.

[13]史婧,孜丽努尔·阿不都许库尔,蔡慧,etal.奥马珠单抗治疗变应性支气管肺曲霉病的疗效与安全性:一项真实世界研究[J].中国临床医学,2024,31(02):161-168.

[14]Eckl-Dorna J. Omalizumab's Impact on Total and Allergen-Specific IgE Levels: A Polyclonal Story [J]. International archives of allergy and immunology, 2016, 169(2): 69-70.

[15]Greenberger P A. Defining the Outcome Markers and Therapeutic Role for Omalizumab in Treatment of Allergic Bronchopulmonary Aspergillosis [J]. The Journal of Allergy and Clinical Immunology In Practice, 2023, 11(3).

[16]Chen P, Yu Y, He L, et al. Efficacy of omalizumab in adult patients with allergic bronchopulmonary aspergillosis: a multicentre study in China [J]. Clinical and experimental medicine, 2024, 24(1): 6.

[17]Wong R, Wong M, Robinson P D, et al. Omalizumab in the Management of Steroid Dependent Allergic Bronchopulmonary Aspergillosis (ABPA) Complicating Cystic Fibrosis [J]. Paediatric Respiratory Reviews, 2013, 14(1): 22-24.

[18]Koutsokera A, Corriveau S, Sykes J, et al. Omalizumab for Asthma and Allergic Bronchopulmonary Aspergillosis in Adults with Cystic Fibrosis [J]. Journal of Cystic Fibrosis, 2019, 19(1): 119-124.

[19]Jaffe J S, Massanari M. In response to dosing omalizumab in allergic asthma [J]. The Journal of allergy and clinical immunology,2007,119(1):255-256.

[20]Walford H H, Doherty T A. Diagnosis and Management of Eosinophilic Asthma: A Us Perspective [J]. Journal of asthma and allergy, 2014, 7.

[21]Kawasaki Y, Nishiki K, Ishizaki T. Successful Treatment with Dupilumab in Mepolizumab-Resistant Allergic Bronchopulmonary Aspergillosis [J]. Respiratory Medicine Case Reports,2023,47:101964-101964.

[22]Ramonell R P, Lee F E-H, Swenson C, et al. Dupilumab Treatment for Allergic Bronchopulmonary Aspergillosis: A Case Series [J]. The Journal of Allergy and Clinical Immunology In Practice,2019,8(2):742-743.

[23]Lamothe P A, Pruett C L H, Smirnova N, et al. Anti-IL-4Ra therapy is superior to other biologic classes in treating allergic bronchopulmonary aspergillosis [J]. The journal of allergy and clinical immunology Global,2025,4(1): 100369.

[24]Altman M C, Lenington J, Bronson S, et al. Combination omalizumab and mepolizumab therapy for refractory allergic bronchopulmonary aspergillosis [J]. The journal of allergy and clinical immunology In practice,2017,5(4):1137-1139.

[25]Tolebeyan A, Mohammadi O, Vaezi Z, et al. Mepolizumab As Possible Treatment for Allergic Bronchopulmonary Aspergillosis: A Review of Eight Cases [J]. Cureus,2020,12.

[26]Hamada T, Katsuta T, Aibara K, et al. Mepolizumab in Allergic Bronchopulmonary Aspergillosis Complicated by Infection [J]. Respiratory medicine case reports, 2023, 45: 101890-101890.

[27]Khatri S, Moore W, Gibson P G, et al. Assessment of the Long-Term Safety of Mepolizumab and Durability of Clinical Response in Patients with Severe Eosinophilic Asthma [J]. Journal of Allergy and Clinical Immunology,2018,143(5):1742-1751.e1747.

[28]Ogata H, Sha K, Kotetsu Y, et al. Tezepelumab Treatment for Allergic Bronchopulmonary Aspergillosis [J]. Respirology Case Reports, 2023, 11(5).

(4 摘要 Views, 7 PDF Downloads)

Refbacks

当前没有refback。

用户名
密码
记住我